SALT LAKE CITY, Utah, Sept. 26, 2023 /PRNewswire/ — DiscGenics, Inc., a privately held, late-stage clinical, biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced that Flagg Flanagan, Chief Executive Officer and Chairman of DiscGenics…Read More
DiscGenics CEO to Present at Upcoming Industry Conferences
